陕西盘龙药业集团股份有限公司关于 公司获得药物临床试验批准通知书的公告

Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of the drug Fluorobiphenyl Patch [1] - The product is designed with a controlled-release membrane, featuring a large drug load, low irritation, and reduced risk of skin allergies, making it suitable for chronic pain conditions [2] - The original research product has not yet been launched in the domestic market and is classified as a Class 3 chemical drug [1] Group 2 - The approval of this clinical trial is expected to enhance the company's product portfolio in the musculoskeletal field, complementing its core products and improving its "internal + external" orthopedic solutions [3] - The market for similar products, such as Fluorobiphenyl Gel Patch, is significant, with sales reaching 2.839 billion yuan in 2024 and 2.350 billion yuan in the first three quarters of 2025 [2]